0001209191-23-021559.txt : 20230329
0001209191-23-021559.hdr.sgml : 20230329
20230329193014
ACCESSION NUMBER: 0001209191-23-021559
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230327
FILED AS OF DATE: 20230329
DATE AS OF CHANGE: 20230329
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hopfner Robert Lorne
CENTRAL INDEX KEY: 0001551966
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39397
FILM NUMBER: 23776775
MAIL ADDRESS:
STREET 1: C/O BAY CITY CAPITAL, LLC
STREET 2: 750 BATTERY STREET, SUITE 400
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94111
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Inozyme Pharma, Inc.
CENTRAL INDEX KEY: 0001693011
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 475129768
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 321 SUMMER STREET
STREET 2: SUITE 400
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 857-330-4340
MAIL ADDRESS:
STREET 1: 321 SUMMER STREET
STREET 2: SUITE 400
CITY: BOSTON
STATE: MA
ZIP: 02210
FORMER COMPANY:
FORMER CONFORMED NAME: Inozyme Pharma, LLC
DATE OF NAME CHANGE: 20161222
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-03-27
0
0001693011
Inozyme Pharma, Inc.
INZY
0001551966
Hopfner Robert Lorne
C/O INOZYME PHARMA, INC.
321 SUMMER STREET SUITE 400
BOSTON
MA
02210
1
0
0
0
0
Common Stock
2023-03-27
4
P
0
51074
3.6952
A
2712228
I
See footnotes
Common Stock
2023-03-28
4
P
0
156766
4.1612
A
2868994
I
See footnotes
The price reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.625 to $3.72, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1).
2,668,450 of the reported shares are held directly by Pivotal bioVenture Partners Fund I, L.P and 43,778 of the reported shares are held by Pivotal bioVenture Partners Fund II, L.P. (collectively, "Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P. ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the "Ultimate General Partner").
Pivotal Partners is wholly-owned by Pivotal Life Sciences Holdings Limited ("Pivotal Life Sciences"). Pivotal Life Sciences is wholly-owned by Nan Fung Life Sciences Holdings Limited ("Nan Fung Life Sciences"), and Nan Fung Life Sciences is wholly owned by NF Investment Holdings LImited ("NFIHL"), which is wholly owned by Nan Fung Group Holdings Limited ("NFGHL"). The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by Pivotal. Mr. Kam Chung Leung, Mr. Frank Kai Shui Seto, Mr. Vincent Sai Sing Cheung, Mr. Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao and Mr. Chun Wai Nelson Tang are the members of the Executive Committee of NFGHL. Robert Hopfner, a managing partner of the Ultimate General Partner, is a member of the board of directors of the Issuer. Such person's and entities disclaim beneficial ownership over such securities except to the extent of any pecuniary interest therein.
The price reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.64 to $4.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (4).
2,690,845 of the reported shares are held directly by Pivotal bioVenture Partners Fund I, L.P and 178,149 of the reported shares are held by Pivotal bioVenture Partners Fund II, L.P.
/s/ Robert Hopfner
2023-03-29